Barclays
ENGN icon

Barclays’s enGene Therapeutics ENGN Stock Holding History

Barclays’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.33K Buy
+342
New +$3.04K ﹤0.01% 4837

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Barclays's ENGN Position: Q1 2026 in Review

Barclays opened a new position in enGene Therapeutics (ENGN) in Q1 2026: 342 shares worth $2.33K. The stake represents ﹤0.01% of the portfolio and ranks #4837 among its holdings.

61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • Barclays held 342 shares of enGene Therapeutics worth $2.33K as of Q1 2026.
  • enGene Therapeutics was a new Barclays position in Q1 2026.
  • enGene Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4837 holding.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.